| Title |
Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, October 2012
|
| DOI | 10.2147/ceor.s34188 |
| Pubmed ID | |
| Authors |
Johanna Lister, Sanja Stanisic, Klaus Kaier, Christian Hagist, Dmitry Gultyaev, Stefan Walzer |
| Abstract |
The purpose of this study was to investigate the savings accrued using bevacizumab-based treatment for non-small-cell lung cancer from the societal perspective, taking only public costs into account, in France, Germany, Italy, and Spain. |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 27% |
| Student > Bachelor | 5 | 19% |
| Student > Ph. D. Student | 3 | 12% |
| Other | 2 | 8% |
| Student > Doctoral Student | 1 | 4% |
| Other | 5 | 19% |
| Unknown | 3 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 38% |
| Economics, Econometrics and Finance | 5 | 19% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Psychology | 2 | 8% |
| Unspecified | 1 | 4% |
| Other | 3 | 12% |
| Unknown | 3 | 12% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2019.
All research outputs
#8,571,053
of 25,457,858 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#202
of 525 outputs
Outputs of similar age
#65,320
of 191,151 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#3
of 10 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 191,151 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.